ALKEM LABORATORIES | TTK HEALTHCARE | ALKEM LABORATORIES/ TTK HEALTHCARE |
|||
---|---|---|---|---|---|
P/E (TTM) | x | 21.9 | 12.0 | 183.0% | View Chart |
P/BV | x | 5.3 | 1.7 | 303.9% | View Chart |
Dividend Yield | % | 0.9 | 0.9 | 103.3% |
![]() ![]() |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
ALKEM LABORATORIES Mar-20 |
TTK HEALTHCARE Mar-19 |
ALKEM LABORATORIES/ TTK HEALTHCARE |
5-Yr Chart Click to enlarge
|
||
High | Rs | 2,720 | 1,215 | 223.9% | |
Low | Rs | 1,660 | 610 | 272.1% | |
Sales per share (Unadj.) | Rs | 697.9 | 444.4 | 157.0% | |
Earnings per share (Unadj.) | Rs | 96.1 | 17.2 | 557.3% | |
Cash flow per share (Unadj.) | Rs | 117.3 | 27.6 | 424.4% | |
Dividends per share (Unadj.) | Rs | 25.00 | 5.00 | 500.0% | |
Dividend yield (eoy) | % | 1.1 | 0.5 | 208.3% | |
Book value per share (Unadj.) | Rs | 515.2 | 177.9 | 289.6% | |
Shares outstanding (eoy) | m | 119.57 | 14.13 | 846.2% | |
Bonus/Rights/Conversions | - | - | - | ||
Price / Sales ratio | x | 3.1 | 2.1 | 152.8% | |
Avg P/E ratio | x | 22.8 | 52.9 | 43.1% | |
P/CF ratio (eoy) | x | 18.7 | 33.0 | 56.6% | |
Price / Book Value ratio | x | 4.3 | 5.1 | 82.9% | |
Dividend payout | % | 26.0 | 29.0 | 89.7% | |
Avg Mkt Cap | Rs m | 261,879 | 12,894 | 2,031.0% | |
No. of employees | `000 | 14.3 | 2.3 | 619.9% | |
Total wages/salary | Rs m | 15,055 | 1,307 | 1,151.9% | |
Avg. sales/employee | Rs Th | 5,822.6 | 2,715.7 | 214.4% | |
Avg. wages/employee | Rs Th | 1,050.5 | 565.3 | 185.8% | |
Avg. net profit/employee | Rs Th | 802.0 | 105.4 | 760.8% |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 83,444 | 6,279 | 1,329.0% | |
Other income | Rs m | 1,042 | 78 | 1,344.8% | |
Total revenues | Rs m | 84,486 | 6,356 | 1,329.2% | |
Gross profit | Rs m | 14,734 | 496 | 2,972.9% | |
Depreciation | Rs m | 2,528 | 147 | 1,723.0% | |
Interest | Rs m | 651 | 34 | 1,924.9% | |
Profit before tax | Rs m | 12,598 | 393 | 3,208.8% | |
Minority Interest | Rs m | 0 | 0 | - | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
Tax | Rs m | 1,105 | 149 | 742.0% | |
Profit after tax | Rs m | 11,493 | 244 | 4,716.1% | |
Gross profit margin | % | 17.7 | 7.9 | 223.7% | |
Effective tax rate | % | 8.8 | 37.9 | 23.1% | |
Net profit margin | % | 13.8 | 3.9 | 354.9% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 54,960 | 2,717 | 2,022.7% | |
Current liabilities | Rs m | 32,433 | 1,571 | 2,064.8% | |
Net working cap to sales | % | 27.0 | 18.3 | 147.9% | |
Current ratio | x | 1.7 | 1.7 | 98.0% | |
Inventory Days | Days | 80 | 32 | 247.4% | |
Debtors Days | Days | 72 | 47 | 154.7% | |
Net fixed assets | Rs m | 32,710 | 991 | 3,300.7% | |
Share capital | Rs m | 239 | 141 | 169.2% | |
"Free" reserves | Rs m | 61,368 | 2,373 | 2,586.1% | |
Net worth | Rs m | 61,607 | 2,514 | 2,450.3% | |
Long term debt | Rs m | 1,592 | 3 | 46,835.3% | |
Total assets | Rs m | 99,433 | 4,158 | 2,391.3% | |
Interest coverage | x | 20.4 | 12.6 | 161.4% | |
Debt to equity ratio | x | 0 | 0 | 1,911.4% | |
Sales to assets ratio | x | 0.8 | 1.5 | 55.6% | |
Return on assets | % | 12.2 | 6.7 | 183.0% | |
Return on equity | % | 18.7 | 9.7 | 192.5% | |
Return on capital | % | 21.0 | 16.9 | 123.8% | |
Exports to sales | % | 19.1 | 3.6 | 531.8% | |
Imports to sales | % | 3.0 | 0.5 | 603.6% | |
Exports (fob) | Rs m | 15,917 | 225 | 7,068.0% | |
Imports (cif) | Rs m | 2,483 | 31 | 8,022.3% | |
Fx inflow | Rs m | 16,061 | 225 | 7,132.0% | |
Fx outflow | Rs m | 2,483 | 71 | 3,491.6% | |
Net fx | Rs m | 13,578 | 154 | 8,811.9% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 5,851 | 173 | 3,380.0% | |
From Investments | Rs m | -7,414 | 97 | -7,682.4% | |
From Financial Activity | Rs m | 792 | -307 | -257.6% | |
Net Cashflow | Rs m | -731 | -38 | 1,939.3% |
Indian Promoters | % | 66.9 | 65.4 | 102.3% | |
Foreign collaborators | % | 0.0 | 0.0 | - | |
Indian inst/Mut Fund | % | 33.1 | 3.7 | 894.6% | |
FIIs | % | 0.0 | 5.2 | - | |
ADR/GDR | % | 0.0 | 0.0 | - | |
Free float | % | 0.0 | 25.8 | - | |
Shareholders | 68,381 | 12,723 | 537.5% | ||
Pledged promoter(s) holding | % | 0.0 | 0.0 | - |
Compare ALKEM LABORATORIES With: STERLING BIOTECH SANOFI INDIA ALEMBIC PHARMA ORCHID PHARMA PFIZER
Compare ALKEM LABORATORIES With: MYLAN (US) ACTAVIS (US) ADCOCK INGRAM (S. Africa) TEVA PHARMA (Israel)
Indian share markets witnessed a sharp sell-off today and ended deep in the red.
For the quarter ended December 2020, TTK HEALTHCARE has posted a net profit of Rs 77 m (up 71.7% YoY). Sales on the other hand came in at Rs 2 bn (up 8.1% YoY). Read on for a complete analysis of TTK HEALTHCARE's quarterly results.
For the quarter ended December 2019, TTK HEALTHCARE has posted a net profit of Rs 45 m (down 8.3% YoY). Sales on the other hand came in at Rs 2 bn (up 11.2% YoY). Read on for a complete analysis of TTK HEALTHCARE's quarterly results.
For the quarter ended June 2019, TTK HEALTHCARE has posted a net profit of Rs 36 m (down 53.8% YoY). Sales on the other hand came in at Rs 2 bn (up 3.2% YoY). Read on for a complete analysis of TTK HEALTHCARE's quarterly results.
Here's an analysis of the annual report of TTK HEALTHCARE for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of TTK HEALTHCARE. Also includes updates on the valuation of TTK HEALTHCARE.
For the quarter ended March 2019, TTK HEALTHCARE has posted a net profit of Rs 50 m (down 38.0% YoY). Sales on the other hand came in at Rs 1 bn (down 3.8% YoY). Read on for a complete analysis of TTK HEALTHCARE's quarterly results.
More Views on NewsLast time the smallcap index crossed 19k a big correction followed. Here's what makes it different this time.
In this video, I'll cover your queries on intraday trading and also share my view on how to decide stop losses and target prices.
A look at what India's top equity mutual funds bought and sold in January 2021.
Do you enjoy reading Tesla and Bitcoin stories? Here's a not so famous small-cap stock to profit from the rise of EVs.
More